ES
XBI icon

Eagle Strategies’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Eagle Strategies’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,700
Closed -$1.96M – 339
2024
Q1 		$1.96M Buy
+20,700
New +$1.92M 0.44% 62

Other funds holding XBI

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Eagle Strategies's XBI Position: Q2 2024 in Review

Eagle Strategies sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 20,700 shares — an estimated $1.96M sold.

Eagle Strategies first reported a position in XBI in Q1 2024 and held it in 1 quarter. The position peaked at $1.96M in Q1 2024. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

  • Eagle Strategies reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
  • Eagle Strategies sold 20,700 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $1.96M.
  • Eagle Strategies first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 1 quarter.
  • Eagle Strategies's State Street SPDR S&P Biotech ETF position peaked at $1.96M in Q1 2024.
  • 761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Eagle Strategies's 13F filing for Q2 2024, filed 8 Aug 2024.